2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4ab,The study included 4438 unique patients with psoriasis (2717 [61.2%] male; mean [SD] age, 45.0 [14.6] years at the time of their first treatment included in the study), 1039 (23.4%) of whom had comorbid psoriatic arthritis. A total of 3790 treatment series from bionaive patients were analyzed: 2646 were with adalimumab, 377 with secukinumab, and 767 with ustekinumab. The 5-year standardized risk of discontinuing ustekinumab was 0.37 (95% CI, 0.33-0.41), which was significantly lower than the standardized risks for adalimumab (0.51; 95% CI, 0.49-0.54) and secukinumab (0.54; 95% CI, 0.48-0.60). A total of 3403 treatment series from bioexperienced patients were analyzed: 790 were with adalimumab, 376 with bimekizumab, 192 with brodalumab, 218 with guselkumab, 556 with ixekizumab, 78 with risankizumab, 466 with secukinumab, and 727 with ustekinumab. The 2-year standardized absolute risk of discontinuing ustekinumab was 0.39 (95% CI, 0.36-0.43). Only bimekizumab (0.27; 95% CI, 0.20-0.34), guselkumab (0.29; 95% CI, 0.22-0.36), and risankizumab (0.25; 95% CI, 0.15-0.36) were associated with a significantly lower standardized absolute risk of discontinuation compared with ustekinumab.31:Taf0,Drug survival is an important measure to help guide treatment selection. However, clinical evidence for newer biologics, including bimekizumab, is limited. To determine the drug survival of biologics used for treating psoriasis in a routine clinical practice setting. This cohort study was based on data from the DERMBIO registry, which includes all patients treated with biologics for psoriasis in Denmark. All adult patients enrolled in DERMBIO from its inception in May 2007 until June 2025 were assessed for eligibility. Data were extracted in June 2025 and analyzed separately among those without previous biologic exposure (bionaive patients) and those with previous biologic exposure (bioexperienced patients). Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. The main outcome was standardized absolute risks of treatment discontinuation at 1, 2, and 5 years. Kaplan-Meier estimator was used to determine crude drug survival estimates and the Aalen-Johansen estimator was used to determine crude cause-specific absolute risks. The study included 4438 unique patients with psoriasis (2717 [61.2%] male; mean [SD] age, 45.0 [14.6] years at the time of their first treatment included in the study), 1039 (23.4%) of whom had comorbid psoriatic arthritis. A total of 3790 treatment series from bionaive patients were analyzed: 2646 were with adalimumab, 377 with secukinumab, and 767 with ustekinumab. The 5-year standardized risk of discontinuing ustekinumab was 0.37 (95% CI, 0.33-0.41), which was significantly lower than the standardized risks for adalimumab (0.51; 95% CI, 0.49-0.54) and secukinumab (0.54; 95% CI, 0.48-0.60). A total of 3403 treatment series from bioexperienced patients were analyzed: 790 were with adalimumab, 376 with bimekizumab, 192 with brodalumab, 218 with guselkumab, 556 with ixekizumab, 78 with risankizumab, 466 with secukinumab, and 727 with ustekinumab. The 2-year standardized absolute risk of discontinuing ustekinumab was 0.39 (95% CI, 0.36-0.43). Only bimekizumab (0.27; 95% CI, 0.20-0.34), guselkumab (0.29; 95% CI, 0.22-0.36), and risankizumab (0.25; 95% CI, 0.15-0.36) were associated with a significantly lower standardized absolute risk of discontinuation compared with ustekinumab. In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting.32:Tfc4, Importance Drug survival is an important measure to help guide treatment selection. However, clinical evidence for newer biologics, including bimekizumab, is limited. Objective To determine the drug survival of biologics used for treating psoriasis in a routine clinical practice setting. Design, Setting, and Participants This cohort study was based on data from the DERMBIO registry, which includes all patients treated with biologics for psoriasis in Denmark. All adult patients enrolled in DERMBIO from its inception in May 2007 until June 2025 were assessed for eligibility. Data were extracted in June 2025 and analyzed separately among those without previous biologic exposure (bionaive patients) and those with previous biologic exposure (bioexperienced patients). Exposures Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. Main Outcomes and Measures The main outcome was standardized absolute risks of treatment discontinuation at 1, 2, and 5 years. Kaplan-Meier estimator was used to determine crude drug survival estimates and the Aalen-Johansen estimator was used to determine crude cause-specific absolute risks. Results The study included 4438 unique patients with psoriasis (2717 [61.2%] male; mean [SD] age, 45.0 [14.6] years at the time of their first treatment included in the study), 1039 (23.4%) of whom had comorbid psoriatic arthritis. A total of 3790 treatment series from bionaive patients were analyzed: 2646 were with adalimumab, 377 with secukinumab, and 767 with ustekinumab. The 5-year standardized risk of discontinuing ustekinumab was 0.37 (95% CI, 0.33-0.41), which was significantly lower than the standardized risks for adalimumab (0.51; 95% CI, 0.49-0.54) and secukinumab (0.54; 95% CI, 0.48-0.60). A total of 3403 treatment series from bioexperienced patients were analyzed: 790 were with adalimumab, 376 with bimekizumab, 192 with brodalumab, 218 with guselkumab, 556 with ixekizumab, 78 with risankizumab, 466 with secukinumab, and 727 with ustekinumab. The 2-year standardized absolute risk of discontinuing ustekinumab was 0.39 (95% CI, 0.36-0.43). Only bimekizumab (0.27; 95% CI, 0.20-0.34), guselkumab (0.29; 95% CI, 0.22-0.36), and risankizumab (0.25; 95% CI, 0.15-0.36) were associated with a significantly lower standardized absolute risk of discontinuation compared with ustekinumab. Conclusions and Relevance In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting. 33:T789,The guideline panel agreed on 16 recommendations, of which 1 is a strong recommendation, 9 are conditional recommendations, and 6 were identified as knowledge gaps. In adult patients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment, and suggests the use of certolizumab pegol or vedolizumab over no treatment. In individuals who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, or guselkumab) rather than a lower-efficacy medication (certolizumab pegol or upadacitinib). In individuals who have previously been exposed to 1 or more advanced therapies, the AGA suggests using a higher efficacy medication (adalimumab, risankizumab, guselkumab, or upadacitinib) or intermediate efficacy medication (ustekinumab or mirikizumab) rather than a lower efficacy medication (vedolizumab or certolizumab pegol). In adult outpatients with moderate-to-severely active CD, the AGA suggests against using thiopurine monotherapy for induction of remission, but suggests using thiopurine monotherapy over no treatment for maintenance of (typically corticosteroid-induced) remission. The AGA suggests using subcutaneous methotrexate for induction and maintenance of remission, but suggests against using oral methotrexate. The AGA suggests using combination therapy with infliximab and thiopurines over infliximab monotherapy, particularly in those naïve to thiopurines. The AGA also suggests using initial advanced therapy over step therapy involving corticosteroids and/or immunomodulators in patients with moderate-to-severely active CD. The panel also proposed key implementation considerations for optimal use of these medications, identified several knowledge gaps, and areas for future research.34:Ta0c,This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacologic management of moderate-to-severely active Crohn's disease (CD). A multidisciplinary panel of clinical experts and methodologists used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations. The guideline panel agreed on 16 recommendations, of which 1 is a strong recommendation, 9 are conditional recommendations, and 6 were identified as knowledge gaps. In adult patients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment, and suggests the use of certolizumab pegol or vedolizumab over no treatment. In individuals who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, or guselkumab) rather than a lower-efficacy medication (certolizumab pegol or upadacitinib). In individuals who have previously been exposed to 1 or more advanced therapies, the AGA suggests using a higher efficacy medication (adalimumab, risankizumab, guselkumab, or upadacitinib) or intermediate efficacy medication (ustekinumab or mirikizumab) rather than a lower efficacy medication (vedolizumab or certolizumab pegol). In adult outpatients with moderate-to-severely active CD, the AGA suggests against using thiopurine monotherapy for induction of remission, but suggests using thiopurine monotherapy over no treatment for maintenance of (typically corticosteroid-induced) remission. The AGA suggests using subcutaneous methotrexate for induction and maintenance of remission, but suggests against using oral methotrexate. The AGA suggests using combination therapy with infliximab and thiopurines over infliximab monotherapy, particularly in those naïve to thiopurines. The AGA also suggests using initial advanced therapy over step therapy involving corticosteroids and/or immunomodulators in patients with moderate-to-severely active CD. The panel also proposed key implementation considerations for optimal use of these medications, identified several knowledge gaps, and areas for future research. This guideline provides a comprehensive, patient-centered, evidence-based approach to the pharmacologic management of patients with moderate-to-severely active CD.35:T8d6,Psoriasis (PsO) in the genital and scalp areas is associated with increased patient burden and impact on quality of life. Effective treatments for PsO in these high-impact areas are essential, though patients are frequently excluded from both biologic clinical trials and treatment because of their often low overall affected body surface area (BSA) despite the disproportionate impact of PsO on their quality of life. Recent guidance also considers these patients as candidates for advanced therapies. Here, we compare the efficacy and safety of risankizumab, an interleukin-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis, versus placebo in the treatment of PsO in the genital or scalp region. UnlIMMited (NCT05969223) is an ongoing phase 4, multicenter, randomized, double-blind, placebo-controlled study for adult patients with moderate-to-severe genital or scalp PsO in patients with < 10% BSA or ≥ 10% BSA involvement. Two parallel studies were conducted with study-G assessing genital PsO and study-S assessing scalp PsO. Patients were randomized 1:1 within each study to receive either 150 mg risankizumab or placebo at weeks 0 and 4. The primary endpoints for the studies were the achievement of static Physician's Global Assessment - Genital (sPGA-G) 0/1 for study-G and scalp Investigator Global Assessment (IGA) 0/1 for study-S, both assessed at week 16. Secondary endpoints are also reported at week 16 in each study assessing skin clearance, symptom resolution, and impact on quality of life. Safety was reported through the first 16 weeks. At week 16, in both studies, a significantly higher proportion of patients receiving risankizumab achieved the primary endpoints compared with placebo. In study-G, 69.1% of patients receiving risankizumab versus 13.0% of patients receiving placebo achieved sPGA-G 0/1 (P < 0.0001). In study-S, 60.8% of patients receiving risankizumab versus 13.0% of patients receiving placebo achieved scalp IGA 0/1 (P < 0.0001). No new safety signals were identified. These results demonstrate that risankizumab is effective in the treatment of genital and scalp psoriasis at week 16, with no new safety signals identified. ClinicalTrials.gov identifier NCT05969223.36:Td0d,Eingun James Song is a consultant, promotional speaker and/or investigator for AbbVie, Alphyn, Alumis, Amgen, Apogee, Bristol Myers Squibb, CorEvitas, Dermavant, Dermbiont, Galderma, Incyte, Johnson & Johnson, Lilly, LEO, Moon Lake, Novartis, Organon, Ortho dermatologics, Pfize, Regeneron, Sanofi, SUN Pharma, UCB, Veradermics, Takeda, Target Registry Timber. Lindsay Ackerman has been an consultant, speaker, and/or investigator for AbbVie, Amgen, ArGEN-X, Artacus, AstraZeneca, Biofronterra, Bristol Myers Squibb, Castle, ChemoCentryx, Corevitas (Corrona), DermTech, Eli Lilly, Helsinn Incyte, Janssen, Kyowa Kirin, Mindera, Novartis, Sanofi, Sun, Timber, Trevi, and UCB. Benjamin Ehst is a speaker, adviser and/or clinical study investigator for AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Celldex, Concert, Dermavant, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, LEO, Merck, Navigator Medicines, Novartis, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB, and Ventyx. Phoebe Rich has served on advisory boards for Alumis, Oruka, and Veradermics and as an investigator for Abbvie, Aflasigma, Allakos, Amgen, Arcutis, Aslan, Bristol-Myers-Squibb, Dermavant, Dermbiont, Dermira, EliLilly, Galderma, Hallux, Incyte, Janssen, Leo, Moberg, Pfizer, Sun, Technoderma, Teva, UCB, and Veradermics. Jerry Bagel has received research funds from Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas (Corrona) Psoriasis Registry, Dermavant, Dermira/UCB, Eli Lilly, Glenmark, Janssen Biotech, Kadmon, Leo Pharma, Lycera, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro, and Valeant; has served as a consultant for AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Novartis, Sun Pharma, and Valeant; and has served as a speaker for AbbVie, Celgene, Eli Lilly, Janssen Biotech, and Novartis. George Michael Lewitt is a consultant, promotional speaker, and/or investigator for AbbVie, Amgen, Arcutis, Bristol Meyers Squibb, Dermavant, Galderma Laboratories, Incyte, Janssen, Lilly, Novan, Novartis, Orthodermatologics, Pfizer, Sanofi, Sun Pharma, UCB, and the CorEvitas PsO and AD registries. Navid Ezra is a speaker, adviser and/or clinical study investigator for AbbVie, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, ChemoCentryx, Dermavant, Eli Lilly, Incyte, Janssen, LEO, Merck, Novartis, Ortho Dermatologics, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB and the CorEvitas registries. Brad Glick is an advisory board member, consultant, speaker and/or investigator for and received honoraria or grants from Amgen, AbbVie, AstraZeneca, Almirall, Acrutis, Bausch Health/Valeant, OrthoDermatologics, Boehringer Ingelheim, Bristol Myers Squibb, Brickell Biotech, Cara Therapeutics, ChemoCentryx, Dermavant, Dermira, Eli Lilly, EPI/Novan Pharmaceuticals, Incyte, Janssen Pharmaceuticals, LEO Pharma, Galderma, Nimbus Lakshmi, Inc, Novartis Pharmaceutical Corporation, Sun Pharma, Pfizer, Sanofi, Regeneron, UCB Biopharmaceuticals and the CorEvitas AD, CorEvitas PSO and PROSE Registries. Dr. Glick is a shareholder of Top MD, LLC. Toni Anschutz, Brenton Bialik, Greg St. John, Arathi Setty, Chenyang Duan, Manish Patel, and Doug Ashley are full time employees of AbbVie receiving a salary and may hold stock and/or stock options.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"risankizumab: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on risankizumab (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/risankizumab\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"risankizumab\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/risankizumab\"}]}}"}}]],["$","$L2f",null,{"title":"risankizumab: Research & Clinical Takeaways","description":"Explore research on risankizumab (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0797","pmid":"42708646","title":"Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0797","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-12T06:20:17.230Z","updated_at":"2026-09-12T06:20:17.230Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sample_size","value":"n=5962","value_numeric":5962},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Level of evidence assigned as 3 (systematic review of heterogeneous, mostly observational studies); no meta-analysis was conducted due to methodological heterogeneity.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Sex tag set to 'female' as the primary dataset covers maternal exposure; paternal exposure studies also exist but are a small subset (3 studies, 281 pregnancies).","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The review included all indications for IL inhibitors (not psoriasis-only), so findings may not be fully generalizable to psoriasis patients specifically.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The sample size (n=5,962) reflects maternal pregnancy exposures across all included studies, not a single trial cohort; the majority originated from pharmacovigilance databases with inherent reporting bias.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-compliant systematic literature review (search date May 2026) evaluated the reproductive safety of IL-12/23, IL-17, and IL-23 inhibitors during pregnancy and with paternal exposure in patients with psoriasis, examining pregnancy and neonatal outcomes across all available study designs.","key_result":"49 publications met inclusion criteria, reporting 5,962 pregnancies with maternal exposure; ustekinumab had the most data (2,933 pregnancies), followed by secukinumab (1,877), risankizumab (589), ixekizumab (296), guselkumab (217), tildrakizumab (32), bimekizumab (11), brodalumab (6), and mirikizumab (1). Cohort-level findings were generally reassuring — no consistent signal for adverse pregnancy or neonatal outcomes — except one study reporting increased risk of small-for-gestational-age infants with ustekinumab. Paternal exposure data were very limited (3 studies, 281 pregnancies).","limitations":"- Most exposures (n=5,074) came from pharmacovigilance databases that capture only adverse events, making incidence rates incalculable and meta-analysis infeasible.\n- Critical confounders (disease activity, exposure timing, comedications) were missing or unreported in the majority of studies; only one study used confounder-adjusted analysis.\n- Data were heavily skewed toward IBD patients, limiting psoriasis-specific and IL-17-specific conclusions.","practice_takeaway":"Available data are broadly reassuring but insufficient to issue definitive safety guidance; clinicians should weigh uncontrolled disease risk against medication uncertainty on a case-by-case basis. Existing psoriasis registries (e.g., BADBIR, BioCAPTURE) should add standardized pregnancy datasets to accelerate evidence generation."}},{"doi":"10.1007/s10620-026-10231-1","pmid":"42704580","title":"IBD Nurse-Led Clinical Pathways to Optimize Patient Safety in Advanced Therapies: A Narrative Review","journal_title":"Digestive Diseases and Sciences","journal_issn":"0163-2116","published_at":"2026-09-07T00:00:00.000Z","url":"https://doi.org/10.1007/s10620-026-10231-1","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-15T06:17:42.129Z","updated_at":"2026-09-15T06:17:42.129Z","tags":[{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"etrasimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"filgotinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"obefazimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"ozanimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"Anti-Integrin","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"Anti-TNF Agent","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"S1P Receptor Modulator","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"Evidence maturity varies considerably across domains: infection screening and infusion safety are well-supported, while remote monitoring and small-molecule nursing roles rest on a more heterogeneous evidence base.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"No sample size applies — this is a narrative review synthesizing existing literature, not a primary study with enrolled participants.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"Sex of study populations is not reported, as this review aggregates evidence across multiple heterogeneous sources.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"The seven nursing domains represent an interpretative synthesis, not a validated clinical framework; they have not undergone formal consensus, feasibility testing, or outcome evaluation.","value_numeric":null}],"summaries":{"what_studied":"This narrative review synthesized clinical, organizational, and nursing evidence on the role of specialist IBD nurses in managing biologic and small-molecule therapies, drawing on ECCO, BSG, and ACG guidelines plus literature up to December 2025 (with an August 2026 update).","key_result":"Seven interrelated nursing practice domains were identified: pretreatment assessment, therapy preparation, IV infusion management, self-administered therapy management, clinical and laboratory monitoring, critical event management, and core knowledge of biologic/small-molecule therapies. An eighth complementary section covers emerging therapies and special contexts (pregnancy, perianal disease, travel, pediatric/adolescent transition).","limitations":"- Narrative design lacks the exhaustiveness, reproducibility, and formal evidence appraisal of a systematic review; relevant sources may have been missed.\n- Included literature is highly heterogeneous (guidelines, observational studies, service reports, digital-health evaluations), limiting comparative conclusions about individual pathway components.\n- No formal framework-development process was conducted (no expert consensus, stakeholder validation, feasibility testing, or implementation evaluation), so the thematic domains should not be treated as a validated clinical framework or standard of care.","practice_takeaway":"IBD nurses should follow structured, protocol-driven pathways across all phases of advanced therapy—from infectious screening and pharmacogenetic testing before initiation, to predefined escalation algorithms for infusion reactions, infections, VTE, and cardiovascular events. Centers developing or expanding IBD nursing services can use the seven domains as an evidence-informed starting point, while recognizing that formal validation and local adaptation are still needed."}},{"doi":"10.1007/s13555-026-01839-2","pmid":"42393457","title":"Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01839-2","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-08T13:26:30.683Z","updated_at":"2026-07-08T13:26:30.683Z","tags":[{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"generic","value":"icotrokinra","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"modality","value":"IL-23 Receptor Blocker","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"study_design","value":"Matching-Adjusted Indirect Comparison (MAIC)","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"Level of evidence assigned as 3 (indirect comparison using individual patient data); this reflects MAIC methodology, which sits below RCT-level evidence.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"No proprietary brand name for icotrokinra was confirmed in the source text; it is listed generically only.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"Sample size for the MAIC was not explicitly reported in the abstract or results; the tag was omitted accordingly.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"The MAIC was sponsored by Johnson & Johnson (risankizumab manufacturer), which may introduce bias favoring risankizumab.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"The paper metadata and full text appear to contain content from a separate conference poster (ICONIC-ADVANCE durability data) embedded within the PDF, which is distinct from the MAIC study being summarized; only the MAIC abstract content was used for extraction.","value_numeric":null}],"summaries":{"what_studied":"This matching-adjusted indirect comparison (MAIC) evaluated the relative efficacy of risankizumab (injectable IL-23 inhibitor) versus icotrokinra (oral IL-23 receptor blocker) in adults with moderate-to-severe plaque psoriasis through week 52, using individual patient data from phase 3 risankizumab trials and published summary data from icotrokinra phase 3 trials (ICONIC-ADVANCE 1 & 2).","key_result":"At week 16, placebo-adjusted response rates significantly favored risankizumab over icotrokinra across all endpoints: PASI 75 (80.6% vs 61.7%; RD +18.9%, 95% CI 11.5–26.4; P<0.001), PASI 90 (71.4% vs 49.9%; RD +21.5%, 95% CI 15.6–27.4; P<0.001), PASI 100 (42.3% vs 29.4%; RD +13.0%, 95% CI 7.9–18.0; P<0.001), IGA 0/1 (77.8% vs 58.4%; RD +19.4%; P<0.001), and IGA 0 (41.6% vs 33.9%; RD +7.7%; P<0.05); differences were consistent through week 52.","limitations":"- No head-to-head trial exists; MAIC relies on cross-trial assumptions that may not fully account for unmeasured confounders.\n- Unanchored analyses at weeks 24 and 52 lack a shared placebo arm, increasing potential for residual bias.\n- The study was funded by the risankizumab manufacturer (AbbVie/J&J sponsorship context), introducing industry conflict of interest.","practice_takeaway":"When choosing between an injectable IL-23 inhibitor (risankizumab) and the new oral IL-23 receptor blocker (icotrokinra) for moderate-to-severe plaque psoriasis, this indirect comparison suggests risankizumab achieves meaningfully higher skin clearance rates at all time points through one year. Clinicians should weigh this efficacy gap against patient preference for an oral therapy, bearing in mind the inherent limitations of cross-trial comparisons."}},{"doi":"10.1111/apt.70783","pmid":"42267647","title":"Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry","journal_title":"Alimentary Pharmacology & Therapeutics","journal_issn":"0269-2813","published_at":"2026-06-10T00:00:00.000Z","url":"https://doi.org/10.1111/apt.70783","source_score":17,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-18T13:24:25.077Z","updated_at":"2026-06-18T13:24:25.077Z","tags":[{"paper_doi":"10.1111/apt.70783","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"sample_size","value":"n=857","value_numeric":857},{"paper_doi":"10.1111/apt.70783","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"study_design","value":"Multicentre Observational Cohort Study","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"warning","value":"Follow-up is short (mean 7.4 months); remission rates may not reflect sustained long-term outcomes.","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"warning","value":"Prior ustekinumab exposure showed lower remission in unadjusted but not adjusted analyses — confounding by indication is possible and should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"warning","value":"Remission was defined clinically (HBI ≤4); no endoscopic, histologic, or biomarker endpoints were reported, which may overestimate true deep remission rates.","value_numeric":null},{"paper_doi":"10.1111/apt.70783","tag_type":"warning","value":"Sex distribution of the cohort is not reported in the abstract; the 'mixed' sex tag is assumed from the general adult population context.","value_numeric":null}],"summaries":{"what_studied":"Real-world effectiveness and safety of risankizumab in 857 adult patients with predominantly refractory Crohn's disease registered in the ENEIDA registry, assessing steroid-free clinical remission (Harvey-Bradshaw Index ≤4, no systemic corticosteroids) at weeks 8–12 and at last follow-up (mean 7.4 months).","key_result":"Steroid-free clinical remission was achieved in 56% at weeks 8–12 and 61% at last follow-up; patients with ≤2 prior biologics had significantly higher remission rates than those with >2 (p<0.001); treatment-related adverse events occurred in 8%, with no serious adverse events.","limitations":"Observational design limits causal inference; short mean follow-up of 7.4 months precludes long-term durability conclusions; lack of endoscopic or biomarker remission data as outcomes.","practice_takeaway":"Risankizumab provides clinically meaningful remission even in highly biologic-refractory Crohn's disease, but earlier use (≤2 prior biologics) yields better outcomes — consider positioning it before exhausting the biologic pipeline. Its favorable safety profile supports use in this complex population."}},{"doi":"10.1007/s13555-026-01809-8","pmid":"42262459","title":"New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-06-09T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01809-8","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-15T13:21:49.802Z","updated_at":"2026-06-15T13:21:49.802Z","tags":[{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"brand","value":"Ilumya","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"condition","value":"Latent Tuberculosis Infection","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"sample_size","value":"n=41","value_numeric":41},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"study_design","value":"Systematic Literature Review","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"Sample size tag reflects number of studies (41), not individual patients, as total patient-level N was not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"The 'impact_flag' of practice_changing is applied cautiously — the review's conclusion that routine LTBI screening may not be required contradicts current guidelines for many biologics, and this is based on indirect/safety-as-secondary evidence rather than dedicated TB-outcome trials.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"The review included case series and observational studies alongside RCTs; study quality is heterogeneous (assessed via RoB2 and NOS tools).","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01809-8","tag_type":"warning","value":"The single LTBI reactivation event in a risankizumab-treated patient was reported in one observational study; the abstract does not provide clinical details (e.g., TB prophylaxis status, country), limiting interpretation.","value_numeric":null}],"summaries":{"what_studied":"This systematic literature review evaluated the risk of latent TB infection (LTBI) reactivation and new TB infections in adults with psoriasis (PsO) or psoriatic arthritis (PsA) treated with IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), with a focus on the Asia-Pacific (APAC) region; 58 publications from 41 studies were included.","key_result":"No LTBI reactivation or new TB cases were observed in 33 of 34 PsO studies and all 8 PsA studies; only one observational study reported a single LTBI reactivation event in a risankizumab-treated PsO patient, including among patients with LTBI who did not complete chemoprophylaxis.","limitations":"- Most included studies were not designed with TB as a primary endpoint, limiting detection sensitivity.\n- Heterogeneous LTBI screening practices across studies and regions reduce comparability.\n- APAC-specific data came from only 9 publications across 8 studies, limiting conclusions for high-TB-burden settings.","practice_takeaway":"IL-23 inhibitors appear to carry minimal TB risk in patients with PsO or PsA, including those with LTBI who have not completed chemoprophylaxis. Routine pre-treatment LTBI screening before starting IL-23 inhibitor therapy may not be necessary, particularly in low-TB-prevalence regions."}},{"doi":"10.1093/bjd/ljag174","pmid":"42082393","title":"Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2026-05-05T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljag174","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-09T13:22:33.628Z","updated_at":"2026-05-09T13:22:33.628Z","tags":[{"paper_doi":"10.1093/bjd/ljag174","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"brand","value":"Enbrel","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"brand","value":"Otezla","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"condition","value":"Serious Infection","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"generic","value":"apremilast","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"sample_size","value":"n=18976","value_numeric":18976},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"warning","value":"Study design is labeled as a registry cohort (observational); the level of evidence reflects this, not a randomized trial.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"warning","value":"The elevated serious infection signals for apremilast and secukinumab vs. adalimumab were not consistent in sensitivity analyses — these should not be interpreted as definitive safety differences.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag174","tag_type":"warning","value":"Treatment episodes (n=46,770) far exceed patient count (n=18,976), meaning many patients switched treatments; channeling bias by disease severity or comorbidity cannot be fully excluded.","value_numeric":null}],"summaries":{"what_studied":"This large UK registry cohort (BADBIR) examined serious infection risk across systemic psoriasis treatments — including biologics (adalimumab, secukinumab, risankizumab, brodalumab, etanercept) and non-biologics (apremilast, standard treatments) — in 18,976 adult patients over 46,770 treatment episodes, using inverse probability weighting and both time-to-first-event and recurrent-event analyses.","key_result":"Overall serious infection incidence was 27.67 per 1,000 person-years; recurrent infection rate in those with prior infection was 78.70 per 1,000 person-years. The more robust recurrent-event (PWP) model showed risankizumab had lower serious infection risk vs. brodalumab (HR 0.74), etanercept (HR 0.75), and standard treatments (HR 0.80). Apparent elevated risks with apremilast (HR 1.53) and secukinumab (HR 1.34) vs. adalimumab in the time-to-first-event model were not consistent across sensitivity analyses. Serious infection-related deaths were rare (IR 1.81 per 1,000 person-years).","limitations":"- Elevated risks for apremilast and secukinumab were not replicated in sensitivity analyses, limiting confidence in those signals.\n- Observational registry design introduces potential residual confounding despite inverse probability weighting.\n- Channeling bias is possible, as sicker or higher-risk patients may have been preferentially prescribed certain agents.","practice_takeaway":"For psoriasis patients at elevated infection risk, risankizumab may offer a relative safety advantage over brodalumab, etanercept, and conventional systemic agents. The apparent higher infection risk with apremilast and secukinumab vs. adalimumab should be interpreted cautiously, as it was not robust across sensitivity analyses."}},{"doi":"10.1001/jamadermatol.2025.5205","pmid":"41499137","title":"Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-01-07T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12780981/","source_score":26,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-10","doi":"10.1001/jamadermatol.2025.5205","days":"14","issn":"2168-6068","rank":"2","field":"Clinical Medicine","score":"26","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.5205","title":"Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"41499137","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.5205","URL":"https://doi.org/10.1001/jamadermatol.2025.5205","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2843485/jamadermatology_schwarz_2026_oi_250064_1766518249.66247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis"],"author":[{"given":"Christopher Willy","family":"Schwarz","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark"}]},{"given":"Lars Erik","family":"Bryld","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark"}]},{"given":"Christoffer Valdemar","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Dermatology, Copenhagen University Hospital–Bispebjerg, Copenhagen, Denmark"}]},{"given":"Kawa Khaled","family":"Ajgeiy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Odense University Hospital, Odense, Denmark"}]},{"given":"Trine","family":"Bertelsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Kasper Fjellhaugen","family":"Hjuler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark"}]},{"given":"Tomas Norman","family":"Dam","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Nykoebing Falster, Denmark"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Mads Kirchheiner","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}]}],"issued":{"date-parts":[[2026,1,7]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T16:31:10Z","timestamp":1767803470000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T18:54:29Z","timestamp":1767812069040,"date-parts":[[2026,1,7]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2843485"}},"subtitle":[],"deposited":{"date-time":"2026-01-07T16:31:11Z","timestamp":1767803471000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1002/14651858.CD011535.pub6","key":"doi250064r1","year":"2023","issue":"7","author":"Sbidian","volume":"7","first-page":null,"unstructured":null,"article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.2909","key":"doi250064r2","year":"2022","issue":"10","author":"Yiu","volume":"158","first-page":"1131","unstructured":null,"article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-022-00722-y","key":"doi250064r3","year":"2022","issue":"6","author":"Torres","volume":"23","first-page":"891","unstructured":null,"article-title":"Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad035","key":"doi250064r4","year":"2023","issue":"6","author":"Strober","volume":"188","first-page":"749","unstructured":null,"article-title":"Bimekizumab maintenance of response through 3?years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2018.0183","key":"doi250064r5","year":"2018","issue":"5","author":"Mason","volume":"154","first-page":"581","unstructured":null,"article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1177/24755303241234292","key":"doi250064r6","year":"2024","issue":"2","author":"Schwarz","volume":"9","first-page":"51","unstructured":null,"article-title":"Characteristics of patients with psoriasis treated with various biologics - a Danish cohort study.","journal-title":"J Psoriasis Psoriatic Arthritis","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2021.0221","key":"doi250064r7","year":"2021","issue":"6","author":"Loft","volume":"157","first-page":"676","unstructured":null,"article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(07)61602-X","key":"doi250064r8","year":"2007","issue":"9596","author":"von Elm","volume":"370","first-page":"1453","unstructured":null,"article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.16102","key":"doi250064r9","year":"2018","issue":"2","author":"Egeberg","volume":"178","first-page":"509","unstructured":null,"article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.semarthrit.2022.151979","key":"doi250064r10","year":"2022","issue":null,"author":"Egeberg","volume":"53","first-page":null,"unstructured":null,"article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries.","journal-title":"Semin Arthritis Rheum","doi-asserted-by":"publisher"},{"DOI":"10.1093/ije/dyr213","key":"doi250064r11","year":"2012","issue":"3","author":"Andersen","volume":"41","first-page":"861","unstructured":null,"article-title":"Competing risks in epidemiology: possibilities and pitfalls.","journal-title":"Int J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.18637/jss.v045.i03","key":"doi250064r12","year":"2011","issue":"3","author":"van Buuren","volume":"45","first-page":"1","unstructured":null,"article-title":"mice: multivariate imputation by chained equations in R.","journal-title":"J Stat Softw","doi-asserted-by":"publisher"},{"DOI":"10.2147/CLEP.S129785","key":"doi250064r13","year":"2017","issue":null,"author":"Pedersen","volume":"9","first-page":"157","unstructured":null,"article-title":"Missing data and multiple imputation in clinical epidemiological research.","journal-title":"Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2082354","key":"doi250064r14","year":"2022","issue":"6","author":"Kojanova","volume":"33","first-page":"2827","unstructured":null,"article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.15251","key":"doi250064r15","year":"2024","issue":"1","author":"Mastorino","volume":"22","first-page":"34","unstructured":null,"article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20739","key":"doi250064r16","year":"2025","issue":"10","author":"Motedayen Aval","volume":"39","first-page":"1785","unstructured":null,"article-title":"Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2024.05.085","key":"doi250064r17","year":"2024","issue":"5","author":"Sood","volume":"91","first-page":"936","unstructured":null,"article-title":"Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2025.04.038","key":"doi250064r18","year":"2025","issue":"3","author":"Blauvelt","volume":"93","first-page":"644","unstructured":null,"article-title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2102383","key":"doi250064r19","year":"2021","issue":"2","author":"Reich","volume":"385","first-page":"142","unstructured":null,"article-title":"Bimekizumab versus secukinumab in plaque psoriasis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdin.2025.04.011","key":"doi250064r20","year":"2025","issue":null,"author":"Lovegrove","volume":"21","first-page":null,"unstructured":null,"article-title":"Exploring bimekizumab for psoriasis treatment: multicentre perspectives from Canada.","journal-title":"JAAD Int","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad429","key":"doi250064r21","year":"2024","issue":"4","author":"Gordon","volume":"190","first-page":"477","unstructured":null,"article-title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3?years of treatment in randomized phase III trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ajd.14254","key":"doi250064r22","year":"2024","issue":"4","author":"Ting","volume":"65","first-page":"350","unstructured":null,"article-title":"Drug survival of biologics in psoriasis: an Australian multicentre retrospective study.","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19701","key":"doi250064r23","year":"2021","issue":"6","author":"Graier","volume":"184","first-page":"1094","unstructured":null,"article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.15157","key":"doi250064r24","year":"2022","issue":"7","author":"Soenen","volume":"47","first-page":"1324","unstructured":null,"article-title":"Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.491","key":"doi250064r25","year":"2024","issue":"5","author":"Schots","volume":"3","first-page":"1499","unstructured":null,"article-title":"Ixekizumab trough concentrations in psoriasis: paving the way towards personalised therapy: a cohort study.","journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1002/jcph.876","key":"doi250064r26","year":"2017","issue":"7","author":"Bruin","volume":"57","first-page":"876","unstructured":null,"article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis.","journal-title":"J Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.04.019","key":"doi250064r27","year":"2018","issue":"10","author":"Reich","volume":"138","first-page":"2168","unstructured":null,"article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2023.04.009","key":"doi250064r28","year":"2023","issue":"11","author":"Thein","volume":"143","first-page":"2211","unstructured":null,"article-title":"Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment - a nationwide cohort study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.1677","key":"doi250064r29","year":"2024","issue":"8","author":"Hjort","volume":"160","first-page":"830","unstructured":null,"article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":29,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":29,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.5205","is_oa":true,"title":"Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis","updated":"2026-01-13T16:36:47+00:00","published_date":"2026-01-07","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12780981/","pmh_id":"oai:pubmedcentral.nih.gov:12780981","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12780981/"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"sample_size","value":"n=4438","value_numeric":4438},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"warning","value":"Bionaive analyses included only three biologics, so results may not generalize across all classes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"warning","value":"Different follow-up windows were used for bionaive (5-year) vs bioexperienced (2-year) estimates, limiting cross-cohort comparisons.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"warning","value":"Some agents had small sample sizes in the bioexperienced group (e.g., risankizumab n=78), increasing uncertainty.","value_numeric":null}],"summaries":{"what_studied":"A Danish registry cohort (DERMBIO) of 4438 adults with psoriasis (2007–2025) evaluated biologic drug survival using standardized absolute risks of discontinuation at 1, 2, and 5 years, analyzed separately for bionaive and bioexperienced patients.","key_result":"Bionaive: 5-year standardized discontinuation risk was 0.37 (95% CI, 0.33-0.41) for ustekinumab vs 0.51 (0.49-0.54) for adalimumab and 0.54 (0.48-0.60) for secukinumab. Bioexperienced: 2-year risk was 0.39 (0.36-0.43) for ustekinumab and lower for bimekizumab 0.27 (0.20-0.34), guselkumab 0.29 (0.22-0.36), and risankizumab 0.25 (0.15-0.36).","limitations":"Bionaive analyses included only adalimumab, secukinumab, and ustekinumab, limiting class-wide comparisons. Some bioexperienced drugs had small sample sizes (e.g., risankizumab n=78), and follow-up windows differed (5-year bionaive vs 2-year bioexperienced), complicating cross-cohort comparisons.","practice_takeaway":"In routine practice, ustekinumab showed better 5-year persistence than adalimumab and secukinumab in bionaive patients; among bioexperienced patients, bimekizumab, guselkumab, and risankizumab had lower 2-year discontinuation risks than ustekinumab. These real-world survival estimates can guide selection of biologics for psoriasis, especially after prior biologic exposure."}},{"doi":"10.1053/j.gastro.2025.09.038","pmid":"41274746","title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease","journal_title":"Gastroenterology","journal_issn":"0016-5085","published_at":"2025-11-23T00:00:00.000Z","url":"https://doi.org/10.1053/j.gastro.2025.09.038","source_score":101,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-11-22","doi":"10.1053/j.gastro.2025.09.038","days":"14","issn":"0016-5085","rank":"1","field":"Clinical Medicine","score":"101","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1053/j.gastro.2025.09.038","title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.","journal":"Gastroenterology","methods":"","results":"$33","abstract":"$34","keywords":["Evidence Synthesis","Inflammatory Bowel Disease","Network Meta-Analysis","Positioning"],"pubmed_id":"41274746","conclusions":"","publication_date":"2025-11-23T00:00:00"},"crossref":{"DOI":"10.1053/j.gastro.2025.09.038","URL":"https://doi.org/10.1053/j.gastro.2025.09.038","ISSN":["0016-5085"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0016508525060913?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0016508525060913?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1397-1448","type":"journal-article","issue":"7","score":1,"title":["AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease"],"author":[{"given":"Frank I.","family":"Scott","sequence":"first","affiliation":[]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[]},{"given":"Benjamin","family":"Click","sequence":"additional","affiliation":[]},{"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[]},{"given":"Gaurav","family":"Syal","sequence":"additional","affiliation":[]},{"given":"John P.","family":"Haydek","sequence":"additional","affiliation":[]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[]},{"given":"Michael D.","family":"Kappelman","sequence":"additional","affiliation":[]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,12]]},"member":"78","prefix":"10.1053","source":"Crossref","volume":"169","created":{"date-time":"2025-11-20T15:58:29Z","timestamp":1763654309000,"date-parts":[[2025,11,20]]},"indexed":{"date-time":"2025-12-02T01:27:12Z","timestamp":1764638832344,"date-parts":[[2025,12,2]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0016508525060913"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease"},{"name":"journaltitle","label":"Journal Title","value":"Gastroenterology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1053/j.gastro.2025.09.038"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 by the AGA Institute."}],"deposited":{"date-time":"2025-12-02T01:24:45Z","timestamp":1764638685000,"date-parts":[[2025,12,2]]},"issn-type":[{"type":"print","value":"0016-5085"}],"published":{"date-parts":[[2025,12]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.15585/mmwr.mm6542a3","key":"10.1053/j.gastro.2025.09.038_bib1","year":"2016","issue":null,"author":"Dahlhamer","volume":"65","first-page":"1166","unstructured":null,"article-title":"Prevalence of inflammatory bowel disease among adults aged ≥18 years — United States, 2015","journal-title":"MMWR Morb Mortal Wkly Rep","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(19)30333-4","key":"10.1053/j.gastro.2025.09.038_bib2","year":"2020","issue":null,"author":null,"volume":"5","first-page":"17","unstructured":null,"article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2023.07.003","key":"10.1053/j.gastro.2025.09.038_bib3","year":"2023","issue":null,"author":"Lewis","volume":"165","first-page":"1197","unstructured":null,"article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2013-305607","key":"10.1053/j.gastro.2025.09.038_bib4","year":"2014","issue":null,"author":"Rungoe","volume":"63","first-page":"1607","unstructured":null,"article-title":"Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10620-021-07200-1","key":"10.1053/j.gastro.2025.09.038_bib5","year":"2022","issue":null,"author":"Tsai","volume":"67","first-page":"2451","unstructured":null,"article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn's Disease in population-based cohort studies","journal-title":"Dig Dis Sci","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2021.04.023","key":"10.1053/j.gastro.2025.09.038_bib6","year":"2021","issue":null,"author":"Singh","volume":"160","first-page":"2512","unstructured":null,"article-title":"AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2016-312648","key":"10.1053/j.gastro.2025.09.038_bib7","year":"2018","issue":null,"author":"Siegel","volume":"67","first-page":"244","unstructured":null,"article-title":"Development of an index to define overall disease severity in IBD","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2014.07.022","key":"10.1053/j.gastro.2025.09.038_bib8","year":"2014","issue":null,"author":"Sandborn","volume":"147","first-page":"702","unstructured":null,"article-title":"Crohn’s disease evaluation and treatment: clinical decision tool","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2013.02.001","key":"10.1053/j.gastro.2025.09.038_bib9","year":"2013","issue":null,"author":"Sultan","volume":"11","first-page":"329","unstructured":null,"article-title":"The AGA institute process for developing clinical practice guidelines part one: grading the evidence","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2025.08.032","key":"10.1053/j.gastro.2025.09.038_bib10","year":"2025","issue":null,"author":"Singh","volume":"169","first-page":"1516","unstructured":null,"article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe Crohn’s disease: 2025 AGA evidence synthesis","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.7326/M22-0514","key":"10.1053/j.gastro.2025.09.038_bib11","year":"2022","issue":null,"author":"El Mikati","volume":"175","first-page":"1154","unstructured":null,"article-title":"A framework for the development of living practice guidelines in health care","journal-title":"Ann Intern Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2023.09.029","key":"10.1053/j.gastro.2025.09.038_bib12","year":"2023","issue":null,"author":"Ananthakrishnan","volume":"165","first-page":"1367","unstructured":null,"article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.dld.2016.09.009","key":"10.1053/j.gastro.2025.09.038_bib13","year":"2017","issue":null,"author":"Casellas","volume":"49","first-page":"152","unstructured":null,"article-title":"Patient preferences for inflammatory bowel disease treatment objectives","journal-title":"Dig Liver Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0016-5085(76)80163-1","key":"10.1053/j.gastro.2025.09.038_bib14","year":"1976","issue":null,"author":"Best","volume":"70","first-page":"439","unstructured":null,"article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2024.10.001","key":"10.1053/j.gastro.2025.09.038_bib15","year":"2024","issue":null,"author":"Singh","volume":"167","first-page":"1307","unstructured":null,"article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/0197-2456(86)90046-2","key":"10.1053/j.gastro.2025.09.038_bib16","year":"1986","issue":null,"author":"DerSimonian","volume":"7","first-page":"177","unstructured":null,"article-title":"Meta-analysis in clinical trials","journal-title":"Control Clin Trials","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2024.10.009","key":"10.1053/j.gastro.2025.09.038_bib17","year":"2025","issue":null,"author":"Solitano","volume":"168","first-page":"344","unstructured":null,"article-title":"Placebo rates in Crohn's disease randomized clinical trials: an individual patient data meta-analysis","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.327.7414.557","key":"10.1053/j.gastro.2025.09.038_bib18","year":"2003","issue":null,"author":"Higgins","volume":"327","first-page":"557","unstructured":null,"article-title":"Measuring inconsistency in meta-analyses","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.d4002","key":"10.1053/j.gastro.2025.09.038_bib19","year":"2011","issue":null,"author":"Sterne","volume":"343","first-page":null,"unstructured":null,"article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj-2022-074495","key":"10.1053/j.gastro.2025.09.038_bib20","year":"2023","issue":null,"author":"Izcovich","volume":"381","first-page":null,"unstructured":null,"article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2017.10.005","key":"10.1053/j.gastro.2025.09.038_bib21","year":"2018","issue":null,"author":"Brignardello-Petersen","volume":"93","first-page":"36","unstructured":null,"article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ibd/izaf085","key":"10.1053/j.gastro.2025.09.038_bib22","year":"2025","issue":null,"author":"Gordon","volume":"31","first-page":"2798","unstructured":null,"article-title":"Developing IBD outcome effect size thresholds to inform research, guidelines, and clinical decisions","journal-title":"Inflamm Bowel Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib23","year":"2016","issue":null,"author":"Alonso-Coello","volume":"353","first-page":null,"unstructured":null,"article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","journal-title":"BMJ","doi-asserted-by":null},{"DOI":"10.1016/S2468-1253(20)30300-9","key":"10.1053/j.gastro.2025.09.038_bib24","year":"2020","issue":null,"author":"Fairbrass","volume":"5","first-page":"1053","unstructured":null,"article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s11938-021-00364-9","key":"10.1053/j.gastro.2025.09.038_bib25","year":"2021","issue":null,"author":"Hashash","volume":"19","first-page":"583","unstructured":null,"article-title":"Health maintenance for adult patients with inflammatory bowel disease","journal-title":"Cur Treat Options Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2009.11.024","key":"10.1053/j.gastro.2025.09.038_bib26","year":"2010","issue":null,"author":"Long","volume":"8","first-page":"268","unstructured":null,"article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2012.05.004","key":"10.1053/j.gastro.2025.09.038_bib27","year":"2012","issue":null,"author":"Long","volume":"143","first-page":"390","unstructured":null,"article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2017.16071","key":"10.1053/j.gastro.2025.09.038_bib28","year":"2017","issue":null,"author":"Lemaitre","volume":"318","first-page":"1679","unstructured":null,"article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2109927","key":"10.1053/j.gastro.2025.09.038_bib29","year":"2022","issue":null,"author":"Ytterberg","volume":"386","first-page":"316","unstructured":null,"article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2015.233","key":"10.1053/j.gastro.2025.09.038_bib30","year":"2015","issue":null,"author":"Peyrin-Biroulet","volume":"110","first-page":"1324","unstructured":null,"article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2020.12.031","key":"10.1053/j.gastro.2025.09.038_bib31","year":"2021","issue":null,"author":"Turner","volume":"160","first-page":"1570","unstructured":null,"article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM199710093371502","key":"10.1053/j.gastro.2025.09.038_bib32","year":"1997","issue":null,"author":"Targan","volume":"337","first-page":"1029","unstructured":null,"article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2006.02.014","key":"10.1053/j.gastro.2025.09.038_bib33","year":"2006","issue":null,"author":"Lemann","volume":"130","first-page":"1054","unstructured":null,"article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(02)08512-4","key":"10.1053/j.gastro.2025.09.038_bib34","year":"2002","issue":null,"author":"Hanauer","volume":"359","first-page":"1541","unstructured":null,"article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2024.05.006","key":"10.1053/j.gastro.2025.09.038_bib35","year":"2024","issue":null,"author":"Hanauer","volume":"167","first-page":"919","unstructured":null,"article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0016-5085(99)70332-X","key":"10.1053/j.gastro.2025.09.038_bib36","year":"1999","issue":null,"author":"Rutgeerts","volume":"117","first-page":"761","unstructured":null,"article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2005.11.030","key":"10.1053/j.gastro.2025.09.038_bib37","year":"2006","issue":null,"author":"Hanauer","volume":"130","first-page":"323","unstructured":null,"article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gut.2006.106781","key":"10.1053/j.gastro.2025.09.038_bib38","year":"2007","issue":null,"author":"Sandborn","volume":"56","first-page":"1232","unstructured":null,"article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.crohns.2011.07.013","key":"10.1053/j.gastro.2025.09.038_bib39","year":"2012","issue":null,"author":"Watanabe","volume":"6","first-page":"160","unstructured":null,"article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1177/1756284820938960","key":"10.1053/j.gastro.2025.09.038_bib40","year":"2020","issue":null,"author":"Chen","volume":"13","first-page":null,"unstructured":null,"article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial","journal-title":"Ther Adv Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.7326/0003-4819-146-12-200706190-00159","key":"10.1053/j.gastro.2025.09.038_bib41","year":"2007","issue":null,"author":"Sandborn","volume":"146","first-page":"829","unstructured":null,"article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","journal-title":"Ann Intern Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2006.11.041","key":"10.1053/j.gastro.2025.09.038_bib42","year":"2007","issue":null,"author":"Colombel","volume":"132","first-page":"52","unstructured":null,"article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2012.01.035","key":"10.1053/j.gastro.2025.09.038_bib43","year":"2012","issue":null,"author":"Rutgeerts","volume":"142","first-page":"1102","unstructured":null,"article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND Trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa067594","key":"10.1053/j.gastro.2025.09.038_bib44","year":"2007","issue":null,"author":"Sandborn","volume":"357","first-page":"228","unstructured":null,"article-title":"Certolizumab pegol for the treatment of Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa062897","key":"10.1053/j.gastro.2025.09.038_bib45","year":"2007","issue":null,"author":"Schreiber","volume":"357","first-page":"239","unstructured":null,"article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2010.04.021","key":"10.1053/j.gastro.2025.09.038_bib46","year":"2010","issue":null,"author":"Sandborn","volume":"8","first-page":"688","unstructured":null,"article-title":"Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1215739","key":"10.1053/j.gastro.2025.09.038_bib47","year":"2013","issue":null,"author":"Sandborn","volume":"369","first-page":"711","unstructured":null,"article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2014.05.008","key":"10.1053/j.gastro.2025.09.038_bib48","year":"2014","issue":null,"author":"Sands","volume":"147","first-page":"618","unstructured":null,"article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00535-019-01647-w","key":"10.1053/j.gastro.2025.09.038_bib49","year":"2020","issue":null,"author":"Watanabe","volume":"55","first-page":"291","unstructured":null,"article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses","journal-title":"J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjab133","key":"10.1053/j.gastro.2025.09.038_bib50","year":"2022","issue":null,"author":"Vermeire","volume":"16","first-page":"27","unstructured":null,"article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1203572","key":"10.1053/j.gastro.2025.09.038_bib51","year":"2012","issue":null,"author":"Sandborn","volume":"367","first-page":"1519","unstructured":null,"article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1602773","key":"10.1053/j.gastro.2025.09.038_bib52","year":"2016","issue":null,"author":"Feagan","volume":"375","first-page":"1946","unstructured":null,"article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2008.07.014","key":"10.1053/j.gastro.2025.09.038_bib53","year":"2008","issue":null,"author":"Sandborn","volume":"135","first-page":"1130","unstructured":null,"article-title":"A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0016-5085(24)05019-4","key":"10.1053/j.gastro.2025.09.038_bib54","year":"2024","issue":null,"author":"Panaccione","volume":"166","first-page":"1057b2","unstructured":null,"article-title":"Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn's disease: results of the GALAXI 2 & 3 phase 3 studies","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2022.01.047","key":"10.1053/j.gastro.2025.09.038_bib55","year":"2022","issue":null,"author":"Sandborn","volume":"162","first-page":"1650","unstructured":null,"article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(24)01762-8","key":"10.1053/j.gastro.2025.09.038_bib56","year":"2024","issue":null,"author":"Ferrante","volume":"404","first-page":"2423","unstructured":null,"article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2021.10.050","key":"10.1053/j.gastro.2025.09.038_bib57","year":"2022","issue":null,"author":"Sands","volume":"162","first-page":"495","unstructured":null,"article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2025.02.033","key":"10.1053/j.gastro.2025.09.038_bib58","year":"2025","issue":null,"author":"Hart","volume":"169","first-page":"308","unstructured":null,"article-title":"Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn’s disease: results from the phase 3 GRAVITI study","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(22)00467-6","key":"10.1053/j.gastro.2025.09.038_bib59","year":"2022","issue":null,"author":"D'Haens","volume":"399","first-page":"2015","unstructured":null,"article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)30570-6","key":"10.1053/j.gastro.2025.09.038_bib60","year":"2017","issue":null,"author":"Feagan","volume":"389","first-page":"1699","unstructured":null,"article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(22)00466-4","key":"10.1053/j.gastro.2025.09.038_bib61","year":"2022","issue":null,"author":"Ferrante","volume":"399","first-page":"2031","unstructured":null,"article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2212728","key":"10.1053/j.gastro.2025.09.038_bib62","year":"2023","issue":null,"author":"Loftus","volume":"388","first-page":"1966","unstructured":null,"article-title":"Upadacitinib induction and maintenance therapy for Crohn’s disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2020.01.047","key":"10.1053/j.gastro.2025.09.038_bib63","year":"2020","issue":null,"author":"Sandborn","volume":"158","first-page":"2123","unstructured":null,"article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjad100","key":"10.1053/j.gastro.2025.09.038_bib64","year":"2023","issue":null,"author":"Solitano","volume":"17","first-page":"1800","unstructured":null,"article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2016.433","key":"10.1053/j.gastro.2025.09.038_bib66","year":"2016","issue":null,"author":"Osterman","volume":"111","first-page":"1806","unstructured":null,"article-title":"Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2012.218","key":"10.1053/j.gastro.2025.09.038_bib67","year":"2012","issue":null,"author":"Lichtenstein","volume":"107","first-page":"1409","unstructured":null,"article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2024.01.003","key":"10.1053/j.gastro.2025.09.038_bib68","year":"2024","issue":null,"author":"Ahuja","volume":"22","first-page":"1286","unstructured":null,"article-title":"Impact of treatment response on risk of serious infections in patients with Crohn's disease: secondary analysis of the PYRAMID registry","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ibd/izy321","key":"10.1053/j.gastro.2025.09.038_bib69","year":"2019","issue":null,"author":"Scott","volume":"25","first-page":"925","unstructured":null,"article-title":"Improved quality of life with anti-TNF therapy compared with continued corticosteroid utilization in Crohn's disease","journal-title":"Inflamm Bowel Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2019.05.010","key":"10.1053/j.gastro.2025.09.038_bib70","year":"2020","issue":null,"author":"Bewtra","volume":"18","first-page":"406","unstructured":null,"article-title":"Variation among patients with Crohn's disease in benefit vs risk preferences and remission time equivalents","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.14309/ctg.0000000000000629","key":"10.1053/j.gastro.2025.09.038_bib71","year":"2023","issue":null,"author":"Hanzel","volume":"14","first-page":null,"unstructured":null,"article-title":"A comparison of treatment effect sizes in matched phase 2 and phase 3 trials of advanced therapeutics in inflammatory bowel disease: systematic review and meta-analysis","journal-title":"Clin Transl Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)30068-5","key":"10.1053/j.gastro.2025.09.038_bib72","year":"2017","issue":null,"author":"Jorgensen","volume":"389","first-page":"2304","unstructured":null,"article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib73","year":"2025","issue":"Suppl 1","author":"Elosua Gonzalez","volume":"19","first-page":null,"unstructured":null,"article-title":"P0990 Real-world effectiveness of upadacitinib induction therapy in Crohn’s disease, with a focus on patients with concomitant IMIDs","journal-title":"J Crohns Colitis","doi-asserted-by":null},{"DOI":"10.14309/01.ajg.0001034600.37922.a6","key":"10.1053/j.gastro.2025.09.038_bib74","year":"2024","issue":"Suppl","author":"Axenfeld","volume":"119","first-page":"S936","unstructured":null,"article-title":"S1308 Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2024.12.023","key":"10.1053/j.gastro.2025.09.038_bib75","year":"2025","issue":null,"author":"Panaccione","volume":"23","first-page":"2012","unstructured":null,"article-title":"Extended risankizumab treatment in patients with Crohn's disease who did not achieve clinical response to induction treatment","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib76","year":"2025","issue":"Suppl","author":"Afzali","volume":"13","first-page":"S576","unstructured":null,"article-title":"Abstract MP582. Guselkumab maintenance dose regimens in patients with high disease activity and severity: subgroup analysis of participants with moderately to severely active Crohn's disease in the GALAXI phase 3 studies","journal-title":"United European Gastroenterol J","doi-asserted-by":null},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib77","year":"2022","issue":null,"author":"Alayo","volume":"4","first-page":null,"unstructured":null,"article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","journal-title":"Crohns Colitis 360","doi-asserted-by":null},{"DOI":"10.1016/j.cgh.2024.05.051","key":"10.1053/j.gastro.2025.09.038_bib78","year":"2025","issue":null,"author":"Battat","volume":"23","first-page":"469","unstructured":null,"article-title":"IBD matchmaking: rational combination therapy","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2011.04.031","key":"10.1053/j.gastro.2025.09.038_bib79","year":"2011","issue":null,"author":"Sandborn","volume":"9","first-page":"670","unstructured":null,"article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(22)00688-2","key":"10.1053/j.gastro.2025.09.038_bib80","year":"2022","issue":null,"author":"Sands","volume":"399","first-page":"2200","unstructured":null,"article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2314585","key":"10.1053/j.gastro.2025.09.038_bib81","year":"2024","issue":null,"author":"Peyrin-Biroulet","volume":"391","first-page":"213","unstructured":null,"article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2025.07.009","key":"10.1053/j.gastro.2025.09.038_bib82","year":"2025","issue":null,"author":"Lee","volume":null,"first-page":null,"unstructured":null,"article-title":"Efficacy of advanced therapies in achieving remission by disease location in Crohn's disease: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2024-334395","key":"10.1053/j.gastro.2025.09.038_bib83","year":"2025","issue":"Suppl 2","author":"Moran","volume":"74","first-page":"s1","unstructured":null,"article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2023.12.023","key":"10.1053/j.gastro.2025.09.038_bib84","year":"2024","issue":null,"author":"Vuyyuru","volume":"22","first-page":"1190","unstructured":null,"article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in crohn's disease: a systematic review and network meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2019.11.267","key":"10.1053/j.gastro.2025.09.038_bib85","year":"2020","issue":null,"author":"Dolinger","volume":"158","first-page":null,"unstructured":null,"article-title":"P082 Anti-TNF efficacy after primary vedolizumab failure in pediatric inflammatory bowel disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjab058","key":"10.1053/j.gastro.2025.09.038_bib86","year":"2021","issue":null,"author":"Bressler","volume":"15","first-page":"1694","unstructured":null,"article-title":"Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000002553","key":"10.1053/j.gastro.2025.09.038_bib87","year":"2024","issue":null,"author":"Chugh","volume":"119","first-page":"468","unstructured":null,"article-title":"Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: results from the PIANO registry","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2024.06.050","key":"10.1053/j.gastro.2025.09.038_bib88","year":"2025","issue":null,"author":"Fudman","volume":"23","first-page":"454","unstructured":null,"article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(25)00017-2","key":"10.1053/j.gastro.2025.09.038_bib89","year":"2025","issue":null,"author":"Panaccione","volume":"10","first-page":"507","unstructured":null,"article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.12.030","key":"10.1053/j.gastro.2025.09.038_bib90","year":"2022","issue":null,"author":"D’Haens","volume":"20","first-page":"2337","unstructured":null,"article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST extension study","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.20818","key":"10.1053/j.gastro.2025.09.038_bib91","year":"2022","issue":null,"author":"Gordon","volume":"186","first-page":"466","unstructured":null,"article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjab093","key":"10.1053/j.gastro.2025.09.038_bib92","year":"2021","issue":null,"author":"Ferrante","volume":"15","first-page":"2001","unstructured":null,"article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: results from the phase 2 open-label extension study","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1136/gut.37.5.674","key":"10.1053/j.gastro.2025.09.038_bib93","year":"1995","issue":null,"author":"Candy","volume":"37","first-page":"674","unstructured":null,"article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/0016-5085(93)90709-L","key":"10.1053/j.gastro.2025.09.038_bib94","year":"1993","issue":null,"author":"Ewe","volume":"105","first-page":"367","unstructured":null,"article-title":"Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib95","year":"1997","issue":null,"author":"Oren","volume":"92","first-page":"2203","unstructured":null,"article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","journal-title":"Am J Gastroenterol","doi-asserted-by":null},{"DOI":"10.1111/j.1572-0241.2008.02024.x","key":"10.1053/j.gastro.2025.09.038_bib96","year":"2008","issue":null,"author":"Reinisch","volume":"103","first-page":"2284","unstructured":null,"article-title":"A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0016-5085(79)90385-8","key":"10.1053/j.gastro.2025.09.038_bib97","year":"1979","issue":null,"author":"Summers","volume":"77","first-page":"847","unstructured":null,"article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/gast.2000.18144","key":"10.1053/j.gastro.2025.09.038_bib98","year":"2000","issue":null,"author":"Markowitz","volume":"119","first-page":"895","unstructured":null,"article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(78)92524-2","key":"10.1053/j.gastro.2025.09.038_bib99","year":"1978","issue":null,"author":"O'Donoghue","volume":"2","first-page":"955","unstructured":null,"article-title":"Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2013.06.009","key":"10.1053/j.gastro.2025.09.038_bib100","year":"2013","issue":null,"author":"Panes","volume":"145","first-page":"766","unstructured":null,"article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM199502023320503","key":"10.1053/j.gastro.2025.09.038_bib101","year":"1995","issue":null,"author":"Feagan","volume":"332","first-page":"292","unstructured":null,"article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib102","year":"1999","issue":null,"author":"Arora","volume":"46","first-page":"1724","unstructured":null,"article-title":"Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial","journal-title":"Hepatogastroenterology","doi-asserted-by":null},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib103","year":"2000","issue":null,"author":"Feagan","volume":null,"first-page":"342L1627","unstructured":null,"article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","journal-title":"N Engl J Med","doi-asserted-by":null},{"DOI":"10.1001/jamadermatol.2015.3029","key":"10.1053/j.gastro.2025.09.038_bib104","year":"2016","issue":null,"author":"Scott","volume":"152","first-page":"164","unstructured":null,"article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00384-006-0202-x","key":"10.1053/j.gastro.2025.09.038_bib105","year":"2007","issue":null,"author":"Crispino","volume":"22","first-page":"553","unstructured":null,"article-title":"Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature","journal-title":"Int J Colorectal Dis","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.1971.03180310117023","key":"10.1053/j.gastro.2025.09.038_bib106","year":"1971","issue":null,"author":"Filip","volume":"216","first-page":"881","unstructured":null,"article-title":"Pulmonary and hepatic complications of methotrexate therapy of psoriasis","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2014.05.015","key":"10.1053/j.gastro.2025.09.038_bib107","year":"2015","issue":null,"author":"Kotlyar","volume":"13","first-page":"847","unstructured":null,"article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2013.402","key":"10.1053/j.gastro.2025.09.038_bib108","year":"2014","issue":null,"author":"Chatu","volume":"109","first-page":"23","unstructured":null,"article-title":"The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2017.07.032","key":"10.1053/j.gastro.2025.09.038_bib109","year":"2017","issue":null,"author":"Feuerstein","volume":"153","first-page":"827","unstructured":null,"article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2023.03.224","key":"10.1053/j.gastro.2025.09.038_bib110","year":"2023","issue":null,"author":"Kappelman","volume":"165","first-page":"149","unstructured":null,"article-title":"Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn's disease: a pragmatic randomized trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa0904492","key":"10.1053/j.gastro.2025.09.038_bib111","year":"2010","issue":null,"author":"Colombel","volume":"362","first-page":"1383","unstructured":null,"article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2013.11.024","key":"10.1053/j.gastro.2025.09.038_bib112","year":"2014","issue":null,"author":"Feagan","volume":"146","first-page":"681","unstructured":null,"article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjw152","key":"10.1053/j.gastro.2025.09.038_bib113","year":"2016","issue":null,"author":"Matsumoto","volume":"10","first-page":"1259","unstructured":null,"article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2013.12.025","key":"10.1053/j.gastro.2025.09.038_bib114","year":"2014","issue":null,"author":"Osterman","volume":"146","first-page":"941","unstructured":null,"article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2019.02.044","key":"10.1053/j.gastro.2025.09.038_bib115","year":"2020","issue":null,"author":"Singh","volume":"18","first-page":"69","unstructured":null,"article-title":"Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2015.06.034","key":"10.1053/j.gastro.2025.09.038_bib116","year":"2015","issue":null,"author":"Jones","volume":"13","first-page":"2233","unstructured":null,"article-title":"Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gut.2006.099978","key":"10.1053/j.gastro.2025.09.038_bib117","year":"2007","issue":null,"author":"Vermeire","volume":"56","first-page":"1226","unstructured":null,"article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2014.12.026","key":"10.1053/j.gastro.2025.09.038_bib118","year":"2015","issue":null,"author":"Yarur","volume":"13","first-page":"1118","unstructured":null,"article-title":"Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2022.10.016","key":"10.1053/j.gastro.2025.09.038_bib119","year":"2023","issue":null,"author":"Yarur","volume":"21","first-page":"2908","unstructured":null,"article-title":"Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2019.09.041","key":"10.1053/j.gastro.2025.09.038_bib120","year":"2020","issue":null,"author":"Sazonovs","volume":"158","first-page":"189","unstructured":null,"article-title":"HLA-DQA1∗05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2023.03.044","key":"10.1053/j.gastro.2025.09.038_bib121","year":"2023","issue":null,"author":"Solitano","volume":"21","first-page":"3019","unstructured":null,"article-title":"HLA-DQA1 ∗05 genotype and immunogenicity to tumor necrosis factor-alpha antagonists: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2019-319758","key":"10.1053/j.gastro.2025.09.038_bib122","year":"2020","issue":null,"author":"Roblin","volume":"69","first-page":"1206","unstructured":null,"article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1111/imj.16504","key":"10.1053/j.gastro.2025.09.038_bib123","year":"2024","issue":null,"author":"Yu","volume":"54","first-page":"1856","unstructured":null,"article-title":"6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy","journal-title":"Intern Med J","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000003573","key":"10.1053/j.gastro.2025.09.038_bib124","year":"2025","issue":null,"author":"Solitano","volume":null,"first-page":null,"unstructured":null,"article-title":"Effectiveness and safety of advanced combination treatment in patients with refractory inflammatory bowel disease or concomitant immune-mediated disease or extraintestinal manifestations: a multicenter Canadian study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.03.034","key":"10.1053/j.gastro.2025.09.038_bib125","year":"2022","issue":null,"author":"Ahmed","volume":"20","first-page":"e361","unstructured":null,"article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2020.07.012","key":"10.1053/j.gastro.2025.09.038_bib126","year":"2021","issue":null,"author":"Hu","volume":"19","first-page":"1366","unstructured":null,"article-title":"Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab","journal-title":"Clin Gastroenterolo Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2020.06.071","key":"10.1053/j.gastro.2025.09.038_bib127","year":"2021","issue":null,"author":"Yzet","volume":"19","first-page":"668","unstructured":null,"article-title":"No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.3390/jcm9103142","key":"10.1053/j.gastro.2025.09.038_bib128","year":"2020","issue":null,"author":"Vaughn","volume":"9","first-page":"3142","unstructured":null,"article-title":"Vedolizumab serum trough concentrations and response to dose escalation in inflammatory bowel disease","journal-title":"J Clin Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.01.002","key":"10.1053/j.gastro.2025.09.038_bib129","year":"2021","issue":null,"author":"Shukla","volume":"19","first-page":"1108","unstructured":null,"article-title":"Therapeutic drug monitoring of non-anti-tumor necrosis factor biologics","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2022-327002","key":"10.1053/j.gastro.2025.09.038_bib130","year":"2022","issue":null,"author":"Kirchgesner","volume":"71","first-page":"1781","unstructured":null,"article-title":"Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00535-019-01582-w","key":"10.1053/j.gastro.2025.09.038_bib131","year":"2019","issue":null,"author":"Hisamatsu","volume":"54","first-page":"860","unstructured":null,"article-title":"Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)","journal-title":"J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1111/apt.14106","key":"10.1053/j.gastro.2025.09.038_bib132","year":"2017","issue":null,"author":"Roblin","volume":"46","first-page":"142","unstructured":null,"article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","journal-title":"Aliment Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1097/MPG.0000000000000684","key":"10.1053/j.gastro.2025.09.038_bib133","year":"2015","issue":null,"author":"Kierkus","volume":"60","first-page":"580","unstructured":null,"article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease","journal-title":"J Pediatr Gastroenterol Nutr","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2008.03.004","key":"10.1053/j.gastro.2025.09.038_bib134","year":"2008","issue":null,"author":"Van Assche","volume":"134","first-page":"1861","unstructured":null,"article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2024-333385","key":"10.1053/j.gastro.2025.09.038_bib135","year":"2025","issue":null,"author":"Gisbert","volume":"74","first-page":"387","unstructured":null,"article-title":"Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(22)00385-5","key":"10.1053/j.gastro.2025.09.038_bib136","year":"2023","issue":null,"author":"Louis","volume":"8","first-page":"215","unstructured":null,"article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/EVIDoa2200061","key":"10.1053/j.gastro.2025.09.038_bib137","year":"2022","issue":null,"author":"Buhl","volume":"1","first-page":null,"unstructured":null,"article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease","journal-title":"NEJM Evid","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2018.04.012","key":"10.1053/j.gastro.2025.09.038_bib138","year":"2018","issue":null,"author":"Kirchgesner","volume":"155","first-page":"337","unstructured":null,"article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.h2809","key":"10.1053/j.gastro.2025.09.038_bib139","year":"2015","issue":null,"author":"Nyboe Andersen","volume":"350","first-page":null,"unstructured":null,"article-title":"Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000001058","key":"10.1053/j.gastro.2025.09.038_bib140","year":"2021","issue":null,"author":"Khan","volume":"116","first-page":"741","unstructured":null,"article-title":"Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients with inflammatory bowel disease and the impact of thiopurines on their risk","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2022.01.019","key":"10.1053/j.gastro.2025.09.038_bib141","year":"2022","issue":null,"author":"Mahmoud","volume":"20","first-page":"2577","unstructured":null,"article-title":"Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(08)60304-9","key":"10.1053/j.gastro.2025.09.038_bib142","year":"2008","issue":null,"author":"D'Haens","volume":"371","first-page":"660","unstructured":null,"article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(15)00068-9","key":"10.1053/j.gastro.2025.09.038_bib143","year":"2015","issue":null,"author":"Khanna","volume":"386","first-page":"1825","unstructured":null,"article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(24)00034-7","key":"10.1053/j.gastro.2025.09.038_bib144","year":"2024","issue":null,"author":"Noor","volume":"9","first-page":"415","unstructured":null,"article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)30317-3","key":"10.1053/j.gastro.2025.09.038_bib145","year":"2017","issue":null,"author":"Kugathasan","volume":"389","first-page":"1710","unstructured":null,"article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2020.7378","key":"10.1053/j.gastro.2025.09.038_bib146","year":"2020","issue":null,"author":"Adler","volume":"3","first-page":null,"unstructured":null,"article-title":"Association between steroid-sparing therapy and the risk of perianal fistulizing complications among young patients with Crohn disease","journal-title":"JAMA Netw Open","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2024-333280","key":"10.1053/j.gastro.2025.09.038_bib147","year":"2025","issue":null,"author":"Adler","volume":"74","first-page":"539","unstructured":null,"article-title":"Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2021-052501","key":"10.1053/j.gastro.2025.09.038_bib148","year":"2022","issue":null,"author":"Constant","volume":"149","first-page":null,"unstructured":null,"article-title":"Delays related to prior authorization in inflammatory bowel disease","journal-title":"Pediatrics","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(21)00474-X","key":"10.1053/j.gastro.2025.09.038_bib149","year":"2022","issue":null,"author":"Danese","volume":"7","first-page":"294","unstructured":null,"article-title":"Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib150","year":"2022","issue":"Suppl 8","author":"Jairath","volume":"10","first-page":"89","unstructured":null,"article-title":"A cluster-randomised controlled trial of an enhanced treatment algorithm for the management of Crohn’s disease: REACT-2","journal-title":"United European Gastroenterol J","doi-asserted-by":null},{"DOI":"10.1136/gutjnl-2019-318256","key":"10.1053/j.gastro.2025.09.038_bib151","year":"2020","issue":null,"author":"Panaccione","volume":"69","first-page":"658","unstructured":null,"article-title":"Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)32641-7","key":"10.1053/j.gastro.2025.09.038_bib152","year":"2018","issue":null,"author":"Colombel","volume":"390","first-page":"2779","unstructured":null,"article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2020.03.039","key":"10.1053/j.gastro.2025.09.038_bib153","year":"2020","issue":null,"author":"Ungaro","volume":"159","first-page":"139","unstructured":null,"article-title":"Deep remission at 1 year prevents progression of early Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.11.030","key":"10.1053/j.gastro.2025.09.038_bib154","year":"2022","issue":null,"author":"Laharie","volume":"20","first-page":"2074","unstructured":null,"article-title":"Steroid-free deep remission at one year does not prevent Crohn's disease progression: long-term data from the TAILORIX Trial","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(14)61908-5","key":"10.1053/j.gastro.2025.09.038_bib155","year":"2015","issue":null,"author":"De Cruz","volume":"385","first-page":"1406","unstructured":null,"article-title":"Crohn's disease management after intestinal resection: a randomised trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2019.11.056","key":"10.1053/j.gastro.2025.09.038_bib156","year":"2020","issue":null,"author":"Christensen","volume":"18","first-page":"2518","unstructured":null,"article-title":"Histologic healing is more strongly associated with clinical outcomes in ileal Crohn's disease than endoscopic healing","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/apt.15190","key":"10.1053/j.gastro.2025.09.038_bib157","year":"2019","issue":null,"author":"Castiglione","volume":"49","first-page":"1026","unstructured":null,"article-title":"One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing","journal-title":"Aliment Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1097/MIB.0000000000001143","key":"10.1053/j.gastro.2025.09.038_bib158","year":"2017","issue":null,"author":"Fernandes","volume":"23","first-page":"1403","unstructured":null,"article-title":"Transmural healing is associated with improved long-term outcomes of patients with Crohn's disease","journal-title":"Inflamm Bowel Dis","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000003465","key":"10.1053/j.gastro.2025.09.038_bib159","year":"2025","issue":null,"author":"Lichtenstein","volume":"120","first-page":"1225","unstructured":null,"article-title":"ACG Clinical Guideline: management of Crohn's disease in adults","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjae091","key":"10.1053/j.gastro.2025.09.038_bib160","year":"2024","issue":null,"author":"Gordon","volume":"18","first-page":"1531","unstructured":null,"article-title":"ECCO Guidelines on Therapeutics in Crohn’s Disease: medical treatment","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,12]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0016508525060913"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Gastroenterology"],"published-print":{"date-parts":[[2025,12]]},"reference-count":159,"published-online":null,"references-count":159,"short-container-title":["Gastroenterology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1053/j.gastro.2025.09.038","is_oa":true,"title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease","updated":"2025-11-23T06:18:26+00:00","published_date":"2025-11-20","best_oa_location":{"url":"https://www.gastrojournal.org/article/S0016-5085(25)06091-3/pdf","pmh_id":null,"url_for_pdf":"https://www.gastrojournal.org/article/S0016-5085(25)06091-3/pdf","url_for_landing_page":"https://doi.org/10.1053/j.gastro.2025.09.038"}}},"created_at":"2025-12-04T03:42:26.941Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"certolizumab pegol","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"Thiopurine","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"warning","value":"As a living guideline, recommendations may change with updates.","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"warning","value":"Efficacy tiers (higher, intermediate, lower) are referenced without quantitative definition in the abstract; consult the full guideline for criteria.","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"warning","value":"This is a clinical practice guideline summary, not primary trial data; effect sizes are not provided in the abstract.","value_numeric":null}],"summaries":{"what_studied":"An AGA living guideline used the GRADE framework to issue pharmacologic recommendations for adults with moderate-to-severely active Crohn’s disease.","key_result":"The panel issued 16 recommendations (1 strong, 9 conditional, 6 knowledge gaps): it recommends infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment, and suggests certolizumab pegol or vedolizumab over no treatment. It advises higher-efficacy agents first-line in advanced-therapy–naïve patients; after prior advanced therapy, it suggests higher-efficacy (adalimumab, risankizumab, guselkumab, upadacitinib) or intermediate-efficacy (ustekinumab, mirikizumab) over lower-efficacy (vedolizumab, certolizumab pegol); avoid thiopurine monotherapy for induction but consider it for maintenance, use subcutaneous not oral methotrexate, favor infliximab plus thiopurine over infliximab alone, and start with advanced therapy rather than step therapy with steroids/immunomodulators.","practice_takeaway":"For adult outpatients with moderate-to-severe Crohn’s disease, start with an advanced therapy and choose a higher-efficacy agent when naïve to advanced treatments; after prior exposure, avoid lower-efficacy options. Do not use thiopurines to induce remission, use subcutaneous methotrexate if chosen, and prefer infliximab plus a thiopurine over infliximab alone."}},{"doi":"10.1007/s13555-025-01544-6","pmid":"41139175","title":"Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2025-10-26T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-025-01544-6","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-30","doi":"10.1007/s13555-025-01544-6","days":"14","issn":"2193-8210","rank":"7","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1007/s13555-025-01544-6","title":"Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16.","journal":"Dermatology and therapy","methods":"","results":"At week 16, in both studies, a significantly higher proportion of patients receiving risankizumab achieved the primary endpoints compared with placebo. In study-G, 69.1% of patients receiving risankizumab versus 13.0% of patients receiving placebo achieved sPGA-G 0/1 (P < 0.0001). In study-S, 60.8% of patients receiving risankizumab versus 13.0% of patients receiving placebo achieved scalp IGA 0/1 (P < 0.0001). No new safety signals were identified.","abstract":"$35","keywords":["Efficacy","Genital psoriasis","IL-23 inhibitor","Risankizumab","Safety","Scalp psoriasis"],"pubmed_id":"41139175","conclusions":"These results demonstrate that risankizumab is effective in the treatment of genital and scalp psoriasis at week 16, with no new safety signals identified.","publication_date":"2025-10-26T00:00:00"},"crossref":{"DOI":"10.1007/s13555-025-01544-6","URL":"https://doi.org/10.1007/s13555-025-01544-6","ISSN":["2193-8210","2190-9172"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01544-6.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s13555-025-01544-6/fulltext.html","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01544-6.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16"],"author":[{"given":"Eingun James","family":"Song","sequence":"first","affiliation":[]},{"given":"Benjamin","family":"Ehst","sequence":"additional","affiliation":[]},{"given":"Brad","family":"Glick","sequence":"additional","affiliation":[]},{"given":"George Michael","family":"Lewitt","sequence":"additional","affiliation":[]},{"given":"Phoebe","family":"Rich","sequence":"additional","affiliation":[]},{"given":"Navid","family":"Ezra","sequence":"additional","affiliation":[]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[]},{"given":"Toni","family":"Anschutz","sequence":"additional","affiliation":[]},{"given":"Brenton","family":"Bialik","sequence":"additional","affiliation":[]},{"given":"Chenyang","family":"Duan","sequence":"additional","affiliation":[]},{"given":"Doug","family":"Ashley","sequence":"additional","affiliation":[]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[]},{"given":"Greg","family":"St. John","sequence":"additional","affiliation":[]},{"given":"Arathi R.","family":"Setty","sequence":"additional","affiliation":[]},{"given":"Lindsay","family":"Ackerman","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100006483","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100006483","name":"AbbVie","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,10,25]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":null,"created":{"date-time":"2025-10-25T17:38:00Z","timestamp":1761413880000,"date-parts":[[2025,10,25]]},"indexed":{"date-time":"2025-10-25T17:40:45Z","timestamp":1761414045920,"date-parts":[[2025,10,25]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000,"date-parts":[[2025,10,25]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000,"date-parts":[[2025,10,25]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s13555-025-01544-6"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"25 July 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"5 September 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"25 October 2025"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"},"order":2,"value":"$36"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"},"order":3,"value":"Study approval was obtained from local ethics committees (Advarra, reference numbers available in the supplementary materials), and the patients provided written informed consent for participation in the study and publication of study data. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki 1964 and its later amendments."}],"deposited":{"date-time":"2025-10-25T17:38:02Z","timestamp":1761413882000,"date-parts":[[2025,10,25]]},"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"published":{"date-parts":[[2025,10,25]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1038/sj.jid.5701140","key":"1544_CR1","year":"2008","issue":"5","author":"RL Smith","volume":"128","first-page":"1325","unstructured":"Smith RL, Warren RB, Eyre S, et al. Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol. 2008;128(5):1325–7.","article-title":null,"journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1544_CR2","year":"2017","issue":"3","author":"M Zhang","volume":"16","first-page":"220","unstructured":"Zhang M, Carter C, Olson WH, et al. Patient preference for dosing frequency based on prior biologic experience. J Drugs Dermatol. 2017;16(3):220–6.","article-title":null,"journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/bjd.17147","key":"1544_CR3","year":"2019","issue":"3","author":"M Larsabal","volume":"180","first-page":"647","unstructured":"Larsabal M, Ly S, Sbidian E, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019;180(3):647–56.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17403","key":"1544_CR4","year":"2019","issue":"2","author":"M Augustin","volume":"181","first-page":"358","unstructured":"Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358–65.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12895-020-00099-7","key":"1544_CR5","year":"2020","issue":"1","author":"A Egeberg","volume":"20","first-page":"3","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3.","article-title":null,"journal-title":"BMC Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.12805","key":"1544_CR6","year":"2016","issue":"5","author":"JF Merola","volume":"41","first-page":"486","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–9.","article-title":null,"journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2018.1453125","key":"1544_CR7","year":"2018","issue":"8","author":"KAP Meeuwis","volume":"29","first-page":"754","unstructured":"Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, et al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatol Treat. 2018;29(8):754–60.","article-title":null,"journal-title":"J Dermatol Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2008.11.890","key":"1544_CR8","year":"2009","issue":"6","author":"CS Chan","volume":"60","first-page":"962","unstructured":"Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962–71.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1544_CR9","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Psoriasis Foundation. Genital Psoriasis Quick Guide. https://www.psoriasis.org/genitals/. Accessed 5 June 25.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1544_CR10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Psoriasis Foundation. Scalp Psoriasis Quick Guide. https://www.psoriasis.org/scalp/. Accessed 5 June 25.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2340/00015555-1885","key":"1544_CR11","year":"2015","issue":"2","author":"KA Meeuwis","volume":"95","first-page":"211","unstructured":"Meeuwis KA, de Hullu JA, IntHout J, et al. Genital psoriasis awareness program: physical and psychological care for patients with genital psoriasis. Acta Derm Venereol. 2015;95(2):211–6.","article-title":null,"journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1544_CR12","year":"2015","issue":"3","author":"A Zampieron","volume":"150","first-page":"309","unstructured":"Zampieron A, Buja A, Fusco M, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150(3):309–16.","article-title":null,"journal-title":"G Ital Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2015.02.1127","key":"1544_CR13","year":"2015","issue":"6","author":"C Ryan","volume":"72","first-page":"978","unstructured":"Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978–83.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.12589","key":"1544_CR14","year":"2018","issue":"3","author":"JF Merola","volume":"31","first-page":null,"unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2023.2287401","key":"1544_CR15","year":"2024","issue":"1","author":"B Strober","volume":"35","first-page":"2287401","unstructured":"Strober B, Callis DK, Mark L, et al. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. J Dermatol Treat. 2024;35(1):2287401.","article-title":null,"journal-title":"J Dermatol Treat","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae360.112","key":"1544_CR16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Amorim GM, Radichewski V, Sponholz ML, Carneiro S. P82 Are nail, scalp and intergluteal cleft psoriasis really risk factors for psoriatic arthritis or are we just repeating previous studies? Br J Dermatol. 2024;191(Suppl_3). https://doi.org/10.1093/bjd/ljae360.112","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)31713-6","key":"1544_CR17","year":"2018","issue":"10148","author":"KB Gordon","volume":"392","first-page":"650","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(19)30952-3","key":"1544_CR18","year":"2019","issue":"10198","author":"K Reich","volume":"394","first-page":"576","unstructured":"Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–86.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19341","key":"1544_CR19","year":"2021","issue":"1","author":"RB Warren","volume":"184","first-page":"50","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–9.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad252","key":"1544_CR20","year":"2023","issue":"5","author":"LF Stein Gold","volume":"189","first-page":"540","unstructured":"Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol. 2023;189(5):540–52.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2023.2220849","key":"1544_CR21","year":"2023","issue":"1","author":"D Orsini","volume":"34","first-page":"2220849","unstructured":"Orsini D, Gargiulo L, Ibba L, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J Dermatol Treat. 2023;34(1):2220849.","article-title":null,"journal-title":"J Dermatol Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.17659","key":"1544_CR22","year":"2025","issue":"4","author":"Y Okubo","volume":"52","first-page":"593","unstructured":"Okubo Y, Murakami M, Kobayashi S, et al. Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: results from the randomized, phase 3 JumPPP study. J Dermatol. 2025;52(4):593–602.","article-title":null,"journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20818","key":"1544_CR23","year":"2022","issue":"3","author":"KB Gordon","volume":"186","first-page":"466","unstructured":"Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–75.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-021-02200-7","key":"1544_CR24","year":"2022","issue":"6","author":"M Megna","volume":"314","first-page":"619","unstructured":"Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–23.","article-title":null,"journal-title":"Arch Dermatol Res","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2081655","key":"1544_CR25","year":"2022","issue":"6","author":"M Megna","volume":"33","first-page":"2813","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatol Treat. 2022;33(6):2813–20.","article-title":null,"journal-title":"J Dermatol Treat","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-025-01474-3","key":"1544_CR26","year":"2025","issue":"9","author":"B Strober","volume":"15","first-page":"2409","unstructured":"Strober B, Patel M, Kaldas MI, et al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification. Dermatol Ther (Heidelb). 2025;15(9):2409–21.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-017-0212-3","key":"1544_CR27","year":"2018","issue":"1","author":"AB Gottlieb","volume":"8","first-page":"33","unstructured":"Gottlieb AB, Kirby B, Ryan C, et al. The development of the GenPs-SFQ to assess the impact of genital psoriasis on sexual health. Dermatol Ther (Heidelb). 2018;8(1):33–44.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-017-0213-2","key":"1544_CR28","year":"2018","issue":"1","author":"AB Gottlieb","volume":"8","first-page":"45","unstructured":"Gottlieb AB, Kirby B, Ryan C, et al. The development of a patient-reported outcome measure for assessment of genital psoriasis symptoms: the genital psoriasis symptoms scale (GPSS). Dermatol Ther (Heidelb). 2018;8(1):45–56.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":null,"key":"1544_CR29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"International Psoriasis Council. Recategorization of Psoriasis Severity. https://psoriasiscouncil.org/education/disease-severity/. Accessed 5 Dec.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1544_CR30","year":"2018","issue":null,"author":"EJ Yang","volume":"8","first-page":"41","unstructured":"Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41–7.","article-title":null,"journal-title":"Psoriasis (Auckl)","doi-asserted-by":null},{"DOI":null,"key":"1544_CR31","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Psoriasis Foundation. Impact of Pain and Itch USA 2024. https://www.psoriasis.org/advance/impact-of-pain-and-itch. Accessed 5 Dec.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s13555-021-00521-z","key":"1544_CR32","year":"2021","issue":"3","author":"M Mosca","volume":"11","first-page":"769","unstructured":"Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021;11(3):769–97.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2019.1577546","key":"1544_CR33","year":"2019","issue":"8","author":"Y Wang","volume":"30","first-page":"775","unstructured":"Wang Y, Coyne K, Sofen H, et al. Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp. J Dermatol Treat. 2019;30(8):775–83.","article-title":null,"journal-title":"J Dermatol Treat","doi-asserted-by":"publisher"},{"DOI":null,"key":"1544_CR34","year":"2016","issue":null,"author":"K Blakely","volume":"6","first-page":"33","unstructured":"Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis (Auckl). 2016;6:33–40.","article-title":null,"journal-title":"Psoriasis (Auckl)","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2024.07.1521","key":"1544_CR35","year":"2024","issue":"6","author":"M Lebwohl","volume":"91","first-page":"1150","unstructured":"Lebwohl M, Bukhalo M, Stein Gold L, et al. A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement. J Am Acad Dermatol. 2024;91(6):1150–7.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19748","key":"1544_CR36","year":"2024","issue":"5","author":"B Strober","volume":"38","first-page":"864","unstructured":"Strober B, Bachelez H, Crowley J, et al. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). J Eur Acad Dermatol Venereol. 2024;38(5):864–72.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2024.07.158","key":"1544_CR37","year":"2024","issue":"3","author":"LS Gold","volume":"91","first-page":"AB38","unstructured":"Gold LS, Tyring SK, Hong HC, et al. 50251 efficacy of risankizumab versus apremilast among patients with scalp or nail psoriasis from the phase 4 IMMpulse study. J Am Acad Dermatol. 2024;91(3):AB38.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1544"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Dermatology and Therapy"],"reference-count":37,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,25]]},"references-count":37,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct05969223"}],"short-container-title":["Dermatol Ther (Heidelb)"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s13555-025-01544-6","is_oa":true,"title":"Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16","updated":"2025-10-27T16:35:26+00:00","published_date":"2025-10-25","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s13555-025-01544-6.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s13555-025-01544-6.pdf","url_for_landing_page":"https://doi.org/10.1007/s13555-025-01544-6"}}},"created_at":"2025-11-05T07:41:18.588Z","updated_at":"2025-11-13T07:40:24.859Z","tags":[{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"condition","value":"Genital Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"condition","value":"Scalp Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"sample_size","value":"n=214","value_numeric":214},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"warning","value":"Industry-funded study with several sponsor-employed authors.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"warning","value":"Minor discrepancy in study-G denominators: efficacy uses risankizumab n=55 while safety uses n=54.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"warning","value":"Two parallel randomized trials are reported within one article; the total sample is split across study-G and study-S.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01544-6","tag_type":"warning","value":"Week-16 interim results only; longer-term (through week 52) outcomes are pending.","value_numeric":null}],"summaries":{"what_studied":"Two parallel, phase 4, multicenter, randomized, double-blind, placebo-controlled trials in adults with moderate-to-severe genital psoriasis (study-G; n=109) or scalp psoriasis (study-S; n=105) compared risankizumab 150 mg at weeks 0 and 4 versus placebo, with efficacy assessed at week 16 and safety through 16 weeks.","key_result":"At week 16, sPGA-G 0/1 was achieved by 38/55 (69.1%) on risankizumab vs 7/54 (13.0%) on placebo (P<0.0001); scalp IGA 0/1 was achieved by 31/51 (60.8%) vs 7/54 (13.0%) (P<0.0001). Adverse events occurred in 19/54 (35.2%) vs 17/54 (31.5%) in study-G and 13/51 (25.5%) vs 15/54 (27.8%) in study-S, with no new safety signals identified.","limitations":"Results are limited to 16 weeks; enrolled patients may not reflect the broader psoriasis population and concurrent special-area disease was not assessed; the study was industry-funded.","practice_takeaway":"In adults with genital or scalp psoriasis, risankizumab 150 mg given at weeks 0 and 4 improved clearance by week 16 versus placebo, with short-term safety consistent with prior experience. Consider IL-23 inhibition when special-area disease drives severity despite low BSA."}}],"initialOffset":9,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"risankizumab"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"risankizumab"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"risankizumab"}}}]]

Papers